Professor Christopher Liddle

Professor of Clinical Pharmacology & Hepatology
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical Research

Telephone +61 2 9845 6086
Fax +61 2 9845 8351

Map

Research interests

Over the past decade Chris' main area of research has been in the functional genomics of human drug metabolism and adaptive responses to toxic xenobiotic (foreign) and endobiotic (endogenous) chemical compounds. An extension of this work is to understand how the liver protects itself from toxic damage, as occurs in liver diseases where the flow of bile is obstructed (cholestatic liver diseases). More recent work has focused on the role of nuclear hormone receptors in hepatic fibrogenesis, particularly the role of the Vitamin D Receptor as a therapeutic target to prevent progression to cirrhosis in patients with chronic liver disease. These research projects have resulted in three patent families, two of which have been commercialized, as well as many highly cited publications. Chris also has interests in advanced information technology systems in the fields of biomedical research and clinical medicine. He is presently working on the bioinformatics of Next-Gen DNA sequencing technologies applied to gene regulation (e.g.; ChIP-Seq and RNA-Seq) and has contributed to very high impact publications, including recent papers in in the journals Nature, Nature Medicine, Cell and Molecular Cell.

Teaching and supervision

Clinical Pharmacology, Drug Metabolism, Liver Diseases, Bioinformatics

International links

Belgium

(Catholic University, Leuven.) Collaboration, Bile Acids in Critically Ill Patients

Netherlands

(Academic Medical Center, Amsterdam.) Collaboration, Pharmacogenomics of Cancer Chemotherapy

Netherlands

(University Medical Center, Groningen.) Collaboration, Hepatocyte Transporters.

United States

(Deltagen Inc., San Mateo, CA.) IP Licensee, Tools for Drug Screening.

United States

(Genentec Inc., San Francisco, CA.) Collaboration, Hepatic Gene Regulation

United States

(Salk Institute for Biological Studies, La Jolla, CA.) Adjunct Professor (appointed 2010)

Selected grants

2015

  • Increasing beige fat to treat obesity; Gunton J, Swarbrick M, Liddle C, Downes M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Exploiting the pharmacokinetic and pharmacodynamic properties of bile acid receptor agonists to treat liver disease; Liddle C, Hebbard L, Downes M; National Health and Medical Research Council (NHMRC)/Project Grants.

2014

  • Novel approaches to target cancer stem cells in liver cancer; Liddle C, Qiao L, Duan W, Hebbard L; Cancer Council New South Wales/Research Project Grants.
  • NanoString nCounter Platform; deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • How do the Vitamin D Receptor activation genes CYP27B1 and CYP24A1 alter susceptibility to autoimmune diseases?; Booth D, Batten M, Stewart G, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study); Gurney H, Balleine R, Wilcken N, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Small Rodent Airlaw Caging System; George J, O'Connell P, Cunningham A, Hawthorne W, Little D, Djordjevic J, Harris D, Hebbard L, Liddle C, Fletcher J; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2010

  • Steroidogenic factor-1, a novel regulator of hepatic stellate cell function; Liddle C, Downes M; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Role of steroidogenic factor-1 and endogenous steriodgenesis in the function of the hepatic stellate cell; Liddle C; DVC Research/Bridging Support Grant.

2008

  • Function of Vitamin D Receptor in Hepatic Non-Parenchymal Cells; Liddle C, Downes M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partnership; Strasser S, George J, McCaughan G, Dore G, Liddle C, Strasser S; Cancer Council New South Wales/Strategic Research Partnership (STREP) Grants.
  • Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partner; McCaughan G, George J, Strasser S, Dore G, Liddle C; Cancer Council New South Wales/Strategic Research Partnership (STREP) Grants.

2006

  • Relationship between levels of circulating cytokines and cytochrome P450-dependent drug metabolism in patients with advanced ovarian cancer; Liddle C; Cancer Institute New South Wales/International Collaboration Grant.
  • Role of nuclear receptors in haptic injury and fibrogenesis; Liddle C, Downes M, London R; National Health and Medical Research Council (NHMRC)/Project Grants.

2005

  • Repression of hepatic drug metabolism by solid tumours; Robertson G, Clarke S, Polly P, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Shared high-speed fibre optic network connection to the Westmead Research Research Hub Members; Dodson J, Liddle C; NSW DEPT OF SC AND MED RSRCH/Research Grant.
  • Expression and regulation of human genes central to drug disposition in the brain; Liddle C, Robertson G; National Health and Medical Research Council (NHMRC)/Project Grants.

2004

  • Molecular mechanisms of feed-forward regulation of bile acid detoxification and elimination in cholestasis; Robertson G, Liddle C, Lehnert A; National Health and Medical Research Council (NHMRC)/Project Grants.

2002

  • Cytochrome P450 CYP3A regulation in humanized transgenic mice; Liddle C, Robertson G; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • Development of a double humanized mouse model; Liddle C; XenoPharm Inc/Consultancy Agreement.
  • Bile acid detoxification by farnesoid X receptor-mediated CYP3A regulation; Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.

2000

  • Transgenomic WAVE 2100 denaturing HPLC system for DNA variant analysis; Farrell G, Clarke C, Cunningham A, deFazio A, Kirk J, Leary J, Liddle C, Manolios N, Mitchell P, Stewart G, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Mechanism of hepatic cytochrome P450 3A4 induction by rifamycins; Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Humoral regulation of human hepatic cytochromes P450; Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Molecular mechanisms of human cytochrome P450 3A4 gene regulation; Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Liddle, C., Stedman, C., Downes, M. (2010). Signaling Pathways in Liver Diseases: PXR and CAR. In J.F. Dufour and P.A. Clavien (Eds.), Signaling Pathways in Liver Diseases, (pp. 333-344). United States of America: Springer.
  • Liddle, C. (2008). Mass in the Liver. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 461-467). Australia: Elsevier.
  • Liddle, C., Stedman, C. (2007). Hepatic Metabolism of Drugs. In Juan Rodes, Jean-Pierre Benhamou, Andres Blei, Juerg Reichen, and Mario Rizzetto (Eds.), The Textbook of Hepatology: From Basic Science to Clinical Practice, (pp. 241-249). USA: Blackwell Publishers.

Journals

  • Zhuang, L., Hulin, J., Gromova, A., Nguyen, T., Yu, R., Liddle, C., Downes, M., Evans, R., Makarenkova, H., Meech, R. (2014). Barx2 and Pax7 Have Antagonistic Functions in Regulation of Wnt Signaling and Satellite Cell Differentiation. Stem Cells, 32(6), 1161-1673. [More Information]
  • Khushi, M., Liddle, C., Clarke, C., Graham, J. (2014). Binding Sites Analyser (BiSA): Software for Genomic Binding Sites Archiving and Overlap Analysis. PLoS One, 9(2), 1-12. [More Information]
  • Suh, J., Jonker, J., Ahmadian, M., Goetz, R., Lackey, D., Osborn, O., Huang, Z., Liu, W., Yoshihara, E., van Dijk, T., Liddle, C., et al (2014). Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature, 513(7518), 436-439. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • Vanwijngaerden, Y., Langouche, L., Derde, S., Liddle, C., Coulter, S., van den Berghe, G., Mesotten, D. (2014). Impact of Parenteral Nutrition Versus Fasting on Hepatic Bile Acid Production and Transport in a Rabbit Model of Prolonged Critical Illness. Shock (Philadelphia): injury, inflammation, and sepsis: laboratory and clinical approaches, 41(1), 48-54. [More Information]
  • Parnell, G., Gatt, P., McKay, F., Schibeci, S., Krupa, M., Powell, J., Visscher, P., Montgomery, G., Lechner-Scott, J., Broadley, S., Liddle, C., Vucic, S., Stewart, G., Booth, D., et al (2014). Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. Multiple Sclerosis Journal, 20(6), 675-685. [More Information]
  • Vanwijngaerden, Y., Langouche, L., Brunner, R., Gielen, M., Casaer, M., Liddle, C., Coulter, S., Wouters, P., Wilmer, A., van den Berghe, G., et al (2014). Withholding Parenteral Nutrition During Critical Illness Increases Plasma Bilirubin but Lowers the Incidence of Biliary Sludge. Hepatology, 60(1), 202-210. [More Information]
  • Ding, N., Yu, R., Subramaniam, N., Sherman, M., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., Liddle, C., et al (2013). A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response. Cell, 153(3), 601-613. [More Information]
  • Reilly, S., Chiang, S., Decker, S., Chang, L., Uhm, M., Larsen, M., Rubin, J., Mowers, J., White, N., Hochberg, I., Liddle, C., et al (2013). An inhibitor of the protein kinases TBK1 and IKK-{epsilon} improves obesity-related metabolic dysfunctions in mice. Nature Medicine, 19(3), 313-321. [More Information]
  • Kacevska, M., Mahns, A., Sharma, R., Clarke, S., Robertson, G., Liddle, C. (2013). Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. Pharmaceutical Research, 30(9), 2270-2278. [More Information]
  • Ding, N., Liddle, C., Evans, R., Downes, M. (2013). Hepatic actions of vitamin D receptor ligands: a sunshine option for chronic liver disease? Expert Review of Clinical Pharmacology, 6(6), 597-599. [More Information]
  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
  • Uhlenhaut, N., Barish, G., Yu, R., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hubner, N., Evans, R. (2013). Insights into Negative Regulation by the Glucocorticoid Receptor from Genome-wide Profiling of Inflammatory Cistromes. Molecular Cell, 49(1), 158-171. [More Information]
  • Ahmadian, M., Suh, J., Hah, N., Liddle, C., Atkins, A., Downes, M., Evans, R. (2013). PPARγ signaling and metabolism: the good, the bad and the future. Nature Medicine, 19(5), 557-566. [More Information]
  • O'Connor, K., Liddle, C. (2013). Prospective data collection of off-label use of rituximab in Australian public hospitals. Internal Medicine Journal, 43(8), 863-870. [More Information]
  • Jonker, J., Liddle, C., Downes, M. (2012). FXR and PXR: Potential therapeutic targets in cholestasis. Journal of Steroid Biochemistry and Molecular Biology, 130(3-5), 147-158. [More Information]
  • Subramaniam, N., Sherman, M., Rao, R., Wilson, C., Coulter, S., Atkins, A., Evans, R., Liddle, C., Downes, M. (2012). Metformin-mediated Bambi expression in hepatic stellate cells induces prosurvival Wnt/β-catenin signaling. Cancer Prevention Research, 5(4), 553-561. [More Information]
  • Cho, H., Zhao, X., Hatori, M., Yu, R., Barish, G., Lam, M., Chong, L., DiTacchio, L., Atkins, A., Glass, C., Liddle, C., et al (2012). Regulation of circadian behaviour and metabolism by REV-ERB-a and REV-ERB-B. Nature, 485(7396), 123-127. [More Information]
  • Vanwijngaerden, Y., Wauters, J., Langouche, L., Perre, S., Liddle, C., Coulter, S., Vanderborght, S., Roskams, T., Wilmer, A., et al (2011). Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology, 54(5), 1741-1752. [More Information]
  • Kacevska, M., Downes, M., Sharma, R., Evans, R., Clarke, S., Liddle, C., Robertson, G. (2011). Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism. Clinical Cancer Research, 17(10), 3170-3180. [More Information]
  • Wu, A., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D., Peterson, A., Sonoda, J. (2011). FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways. PLoS One, 6(3, Article number e17868), e17868-1-e17868-11. [More Information]
  • Chmiel, K., Suan, D., Liddle, C., Nankivell (Nankievell), B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., Kefford, R. (2011). Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. Journal of Clinical Oncology, 29(9), 237-240. [More Information]
  • Suan, D., O'Connor, K., Booth, D., Liddle, C., Stewart, G. (2011). Voriconazole toxicity related to polymorphisms in CYP2C19. Internal Medicine Journal, 41(4), 364-365. [More Information]
  • Hilmer, S., Seale, J., Le Couteur, D., Crampton, R., Liddle, C. (2009). Do medical courses adequately prepare interns for safe and effective prescribing in New South Wales public hospitals? Internal Medicine Journal, 39(7), 428-434. [More Information]
  • Jonker, J., Stedman, C., Liddle, C., Downes, M. (2009). Hepatobiliary ABC transporters: physiology, regulation and implications for disease. Frontiers in Bioscience, 14, 4904-4920. [More Information]
  • Sharma, R., Kacevska, M., London, R., Clarke, S., Liddle, C., Robertson, G. (2008). Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. British Journal of Cancer, 98(1), 91-97. [More Information]
  • Robertson, G., Liddle, C., Clarke, S. (2008). Inflammation and Altered Drug Clearance in Cancer: Transcriptional Repression of a Human CYP3A4 Transgene in Tumor-bearing Mice. Pharmacology and Therapeutics, 83(6), 894-897. [More Information]
  • Kacevska, M., Robertson, G., Clarke, S., Liddle, C. (2008). Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opinion on Drug Metabolism and Toxicology, 4(2), 137-149. [More Information]
  • Downes, M., Liddle, C. (2008). Look who's talking: nuclear receptors in the liver and gastrointestinal tract. Cell Metabolism, 7(3), 195-199. [More Information]
  • George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics, 5(1), 49-59. [More Information]
  • Morgan, E., Goralski, K., Piquette-Miller, M., Renton, K., Robertson, G., Chaluvadi, M., Charles, K., Clarke, S., Kacevska, M., Liddle, C., et al (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition, 36(2), 205-216. [More Information]
  • Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle, C., Clarke, S. (2008). Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clinical Colorectal Cancer, 7(5), 331-337. [More Information]
  • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. (2008). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research, 14(3), 817-825. [More Information]
  • Klumpen, H., Liddle, C., Gurney, H. (2008). Transporter pumps and imatinib: A cause of pharmacokinetic resistance? Cancer Biology & Therapy, 7(3), 416-418. [More Information]
  • Sharma, R., Koller, L., Barclay, P., Liddle, C. (2007). Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales. Internal Medicine Journal, 37(8), 569-571. [More Information]
  • Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J., Evans, R., Downes, M. (2006). Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 103(30), 11323-11328. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]
  • Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J., Moore, D., Evans, R., Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 102(6), 2063-2068. [More Information]
  • Sonoda, J., Chong, L., Downes, M., Barish, G., Coulter, S., Liddle, C., Lee, C., Evans, R. (2005). Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 102(6), 2198-203. [More Information]
  • Esteban, L., Fong, C., Amr, D., Cock, T., Allison, S., Flanagan, J., Liddle, C., Eisman, J., Gardiner, E. (2005). Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochemical and Biophysical Research Communications, 334(1), 9-15. [More Information]
  • Liddle, C., Rangan, G., Coombes, J., Mreich, E. (2005). Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney International. [More Information]
  • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. Pharmacology and Therapeutics, 75(6), 529-538. [More Information]
  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644.
  • Stedman, C., Robertson, G., Coulter, S., Liddle, C. (2004). Feed-Forward Regulation Of Bile Acid Detoxification By Cyp3A4: Studies In Humanized Transgenic Mice. Journal of Biological Chemistry, 279(12), 11336-11346.
  • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]
  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390.
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
  • Mesotten, D., Van den Berghe, G., Liddle, C., Coulter, S., McDougall, F., Baxter, R., Delhanty, P. (2003). Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology, 144(9), 4008-4017.
  • Liddle, C., Robertson, G. (2003). Predicting inductive drug-drug interactions. Pharmacogenomics, 4(2), 141-152.
  • Robertson, G., Field, J., Goodwin, B., Bierach, S., Tran, M., Lehnert, A., Liddle, C. (2003). Transgenic mouse models of human CYP3A4 gene regulation. Molecular Pharmacology, 64(1), 42-50.
  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009.
  • Farrell, G., Liddle, C. (2002). Drugs and the liver updated, 2002. Seminars in Liver Disease, 22(2), 109-113.
  • Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149.
  • Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379.
  • Liddle, C., Goodwin, B. (2002). Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Seminars in Liver Disease, 22(2), 115-122.
  • Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409.
  • Spurdle, A., Goodwin, B., Hodgson, E., Liddle, C., Hopper, J., Chen, X., Purdie, D., McCredie, M., Giles, G., Chenevix-Trench, G. (2002). The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics and Genomics, 12(5), 355-366.
  • Goodwin, B., Hodgson, E., D'Costa, D., Robertson, G., Liddle, C. (2002). Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Molecular Pharmacology, 62, 359-365.
  • Amr, D., Liddle, C. (2001). A novel polymorphism affects transcription of the CYP3A4 gene. Journal of Gastroenterology and Hepatology, 16.
  • Stedman, C., Robertson, G., Liddle, C., Field, J. (2001). Hepatoprotective response to cholestasis: bile duct ligation activates transcription of a human activates transcription of a human CYP3A4/LACZ transgene in mice. Journal of Gastroenterology and Hepatology, 16.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum leptin is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Journal of Gastroenterology and Hepatology, 16.
  • Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.

Conferences

  • Sharma, R., Koller, L., Liddle, C., Barclay, P. (2006). Retrospective evaluation of the use of rituximab in a renal transplant population. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Asia Pacific Digestive Week 2001, : World Scientific Publishing.

Patents

  • Liddle, C., Goodwin, B. (2013). Xenobiotic Related Induction of Gene Expression. Patent No. 2333016, 7638614, DK/EP 2154250, EP 2154250. Canada, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland, United Kingdom.
  • Liddle, C., Goodwin, B., Robertson, G. (2012). P450 Gene Regulation. Patent No. 2007249083, 2426959, 8088968. Canada.
  • Goodwin, B., Liddle, C. (2010). Xenobiotic Related Induction of Gene Expression of Cytochrome P450 CYP3A4. Patent No. 1082437, 4446603, 69941813.5, 99923306.7. Germany, Spain.
  • Liddle, C., Goodwin, B., Robertson, G. (2009). Transgenic Animals For Analysing CYP3A4 Cytochrome P450 Gene Regulation. Patent No. 7531712.
  • Liddle, C., Goodwin, B. (2006). Cytochrome P450 Transcriptional Enhancer Nucleic Acid Molecule. Patent No. 6984489.
  • Liddle, C., Goodwin, B. (2006). Patent No. 6984489.

2014

  • Zhuang, L., Hulin, J., Gromova, A., Nguyen, T., Yu, R., Liddle, C., Downes, M., Evans, R., Makarenkova, H., Meech, R. (2014). Barx2 and Pax7 Have Antagonistic Functions in Regulation of Wnt Signaling and Satellite Cell Differentiation. Stem Cells, 32(6), 1161-1673. [More Information]
  • Khushi, M., Liddle, C., Clarke, C., Graham, J. (2014). Binding Sites Analyser (BiSA): Software for Genomic Binding Sites Archiving and Overlap Analysis. PLoS One, 9(2), 1-12. [More Information]
  • Suh, J., Jonker, J., Ahmadian, M., Goetz, R., Lackey, D., Osborn, O., Huang, Z., Liu, W., Yoshihara, E., van Dijk, T., Liddle, C., et al (2014). Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature, 513(7518), 436-439. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • Vanwijngaerden, Y., Langouche, L., Derde, S., Liddle, C., Coulter, S., van den Berghe, G., Mesotten, D. (2014). Impact of Parenteral Nutrition Versus Fasting on Hepatic Bile Acid Production and Transport in a Rabbit Model of Prolonged Critical Illness. Shock (Philadelphia): injury, inflammation, and sepsis: laboratory and clinical approaches, 41(1), 48-54. [More Information]
  • Parnell, G., Gatt, P., McKay, F., Schibeci, S., Krupa, M., Powell, J., Visscher, P., Montgomery, G., Lechner-Scott, J., Broadley, S., Liddle, C., Vucic, S., Stewart, G., Booth, D., et al (2014). Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. Multiple Sclerosis Journal, 20(6), 675-685. [More Information]
  • Vanwijngaerden, Y., Langouche, L., Brunner, R., Gielen, M., Casaer, M., Liddle, C., Coulter, S., Wouters, P., Wilmer, A., van den Berghe, G., et al (2014). Withholding Parenteral Nutrition During Critical Illness Increases Plasma Bilirubin but Lowers the Incidence of Biliary Sludge. Hepatology, 60(1), 202-210. [More Information]

2013

  • Ding, N., Yu, R., Subramaniam, N., Sherman, M., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., Liddle, C., et al (2013). A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response. Cell, 153(3), 601-613. [More Information]
  • Reilly, S., Chiang, S., Decker, S., Chang, L., Uhm, M., Larsen, M., Rubin, J., Mowers, J., White, N., Hochberg, I., Liddle, C., et al (2013). An inhibitor of the protein kinases TBK1 and IKK-{epsilon} improves obesity-related metabolic dysfunctions in mice. Nature Medicine, 19(3), 313-321. [More Information]
  • Kacevska, M., Mahns, A., Sharma, R., Clarke, S., Robertson, G., Liddle, C. (2013). Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. Pharmaceutical Research, 30(9), 2270-2278. [More Information]
  • Ding, N., Liddle, C., Evans, R., Downes, M. (2013). Hepatic actions of vitamin D receptor ligands: a sunshine option for chronic liver disease? Expert Review of Clinical Pharmacology, 6(6), 597-599. [More Information]
  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
  • Uhlenhaut, N., Barish, G., Yu, R., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hubner, N., Evans, R. (2013). Insights into Negative Regulation by the Glucocorticoid Receptor from Genome-wide Profiling of Inflammatory Cistromes. Molecular Cell, 49(1), 158-171. [More Information]
  • Ahmadian, M., Suh, J., Hah, N., Liddle, C., Atkins, A., Downes, M., Evans, R. (2013). PPARγ signaling and metabolism: the good, the bad and the future. Nature Medicine, 19(5), 557-566. [More Information]
  • O'Connor, K., Liddle, C. (2013). Prospective data collection of off-label use of rituximab in Australian public hospitals. Internal Medicine Journal, 43(8), 863-870. [More Information]
  • Liddle, C., Goodwin, B. (2013). Xenobiotic Related Induction of Gene Expression. Patent No. 2333016, 7638614, DK/EP 2154250, EP 2154250. Canada, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland, United Kingdom.

2012

  • Jonker, J., Liddle, C., Downes, M. (2012). FXR and PXR: Potential therapeutic targets in cholestasis. Journal of Steroid Biochemistry and Molecular Biology, 130(3-5), 147-158. [More Information]
  • Subramaniam, N., Sherman, M., Rao, R., Wilson, C., Coulter, S., Atkins, A., Evans, R., Liddle, C., Downes, M. (2012). Metformin-mediated Bambi expression in hepatic stellate cells induces prosurvival Wnt/β-catenin signaling. Cancer Prevention Research, 5(4), 553-561. [More Information]
  • Cho, H., Zhao, X., Hatori, M., Yu, R., Barish, G., Lam, M., Chong, L., DiTacchio, L., Atkins, A., Glass, C., Liddle, C., et al (2012). Regulation of circadian behaviour and metabolism by REV-ERB-a and REV-ERB-B. Nature, 485(7396), 123-127. [More Information]
  • Liddle, C., Goodwin, B., Robertson, G. (2012). P450 Gene Regulation. Patent No. 2007249083, 2426959, 8088968. Canada.

2011

  • Vanwijngaerden, Y., Wauters, J., Langouche, L., Perre, S., Liddle, C., Coulter, S., Vanderborght, S., Roskams, T., Wilmer, A., et al (2011). Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology, 54(5), 1741-1752. [More Information]
  • Kacevska, M., Downes, M., Sharma, R., Evans, R., Clarke, S., Liddle, C., Robertson, G. (2011). Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism. Clinical Cancer Research, 17(10), 3170-3180. [More Information]
  • Wu, A., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D., Peterson, A., Sonoda, J. (2011). FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways. PLoS One, 6(3, Article number e17868), e17868-1-e17868-11. [More Information]
  • Chmiel, K., Suan, D., Liddle, C., Nankivell (Nankievell), B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., Kefford, R. (2011). Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. Journal of Clinical Oncology, 29(9), 237-240. [More Information]
  • Suan, D., O'Connor, K., Booth, D., Liddle, C., Stewart, G. (2011). Voriconazole toxicity related to polymorphisms in CYP2C19. Internal Medicine Journal, 41(4), 364-365. [More Information]

2010

  • Liddle, C., Stedman, C., Downes, M. (2010). Signaling Pathways in Liver Diseases: PXR and CAR. In J.F. Dufour and P.A. Clavien (Eds.), Signaling Pathways in Liver Diseases, (pp. 333-344). United States of America: Springer.
  • Goodwin, B., Liddle, C. (2010). Xenobiotic Related Induction of Gene Expression of Cytochrome P450 CYP3A4. Patent No. 1082437, 4446603, 69941813.5, 99923306.7. Germany, Spain.

2009

  • Hilmer, S., Seale, J., Le Couteur, D., Crampton, R., Liddle, C. (2009). Do medical courses adequately prepare interns for safe and effective prescribing in New South Wales public hospitals? Internal Medicine Journal, 39(7), 428-434. [More Information]
  • Jonker, J., Stedman, C., Liddle, C., Downes, M. (2009). Hepatobiliary ABC transporters: physiology, regulation and implications for disease. Frontiers in Bioscience, 14, 4904-4920. [More Information]
  • Liddle, C., Goodwin, B., Robertson, G. (2009). Transgenic Animals For Analysing CYP3A4 Cytochrome P450 Gene Regulation. Patent No. 7531712.

2008

  • Sharma, R., Kacevska, M., London, R., Clarke, S., Liddle, C., Robertson, G. (2008). Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. British Journal of Cancer, 98(1), 91-97. [More Information]
  • Robertson, G., Liddle, C., Clarke, S. (2008). Inflammation and Altered Drug Clearance in Cancer: Transcriptional Repression of a Human CYP3A4 Transgene in Tumor-bearing Mice. Pharmacology and Therapeutics, 83(6), 894-897. [More Information]
  • Kacevska, M., Robertson, G., Clarke, S., Liddle, C. (2008). Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opinion on Drug Metabolism and Toxicology, 4(2), 137-149. [More Information]
  • Downes, M., Liddle, C. (2008). Look who's talking: nuclear receptors in the liver and gastrointestinal tract. Cell Metabolism, 7(3), 195-199. [More Information]
  • Liddle, C. (2008). Mass in the Liver. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 461-467). Australia: Elsevier.
  • George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics, 5(1), 49-59. [More Information]
  • Morgan, E., Goralski, K., Piquette-Miller, M., Renton, K., Robertson, G., Chaluvadi, M., Charles, K., Clarke, S., Kacevska, M., Liddle, C., et al (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition, 36(2), 205-216. [More Information]
  • Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle, C., Clarke, S. (2008). Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clinical Colorectal Cancer, 7(5), 331-337. [More Information]
  • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. (2008). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research, 14(3), 817-825. [More Information]
  • Klumpen, H., Liddle, C., Gurney, H. (2008). Transporter pumps and imatinib: A cause of pharmacokinetic resistance? Cancer Biology & Therapy, 7(3), 416-418. [More Information]

2007

  • Sharma, R., Koller, L., Barclay, P., Liddle, C. (2007). Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales. Internal Medicine Journal, 37(8), 569-571. [More Information]
  • Liddle, C., Stedman, C. (2007). Hepatic Metabolism of Drugs. In Juan Rodes, Jean-Pierre Benhamou, Andres Blei, Juerg Reichen, and Mario Rizzetto (Eds.), The Textbook of Hepatology: From Basic Science to Clinical Practice, (pp. 241-249). USA: Blackwell Publishers.

2006

  • Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J., Evans, R., Downes, M. (2006). Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 103(30), 11323-11328. [More Information]
  • Liddle, C., Goodwin, B. (2006). Cytochrome P450 Transcriptional Enhancer Nucleic Acid Molecule. Patent No. 6984489.
  • Sharma, R., Koller, L., Liddle, C., Barclay, P. (2006). Retrospective evaluation of the use of rituximab in a renal transplant population. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]
  • Liddle, C., Goodwin, B. (2006). Patent No. 6984489.

2005

  • Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J., Moore, D., Evans, R., Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 102(6), 2063-2068. [More Information]
  • Sonoda, J., Chong, L., Downes, M., Barish, G., Coulter, S., Liddle, C., Lee, C., Evans, R. (2005). Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 102(6), 2198-203. [More Information]
  • Esteban, L., Fong, C., Amr, D., Cock, T., Allison, S., Flanagan, J., Liddle, C., Eisman, J., Gardiner, E. (2005). Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochemical and Biophysical Research Communications, 334(1), 9-15. [More Information]
  • Liddle, C., Rangan, G., Coombes, J., Mreich, E. (2005). Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney International. [More Information]

2004

  • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. Pharmacology and Therapeutics, 75(6), 529-538. [More Information]
  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644.
  • Stedman, C., Robertson, G., Coulter, S., Liddle, C. (2004). Feed-Forward Regulation Of Bile Acid Detoxification By Cyp3A4: Studies In Humanized Transgenic Mice. Journal of Biological Chemistry, 279(12), 11336-11346.
  • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]

2003

  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390.
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
  • Mesotten, D., Van den Berghe, G., Liddle, C., Coulter, S., McDougall, F., Baxter, R., Delhanty, P. (2003). Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology, 144(9), 4008-4017.
  • Liddle, C., Robertson, G. (2003). Predicting inductive drug-drug interactions. Pharmacogenomics, 4(2), 141-152.
  • Robertson, G., Field, J., Goodwin, B., Bierach, S., Tran, M., Lehnert, A., Liddle, C. (2003). Transgenic mouse models of human CYP3A4 gene regulation. Molecular Pharmacology, 64(1), 42-50.

2002

  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009.
  • Farrell, G., Liddle, C. (2002). Drugs and the liver updated, 2002. Seminars in Liver Disease, 22(2), 109-113.
  • Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149.
  • Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379.
  • Liddle, C., Goodwin, B. (2002). Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Seminars in Liver Disease, 22(2), 115-122.
  • Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409.
  • Spurdle, A., Goodwin, B., Hodgson, E., Liddle, C., Hopper, J., Chen, X., Purdie, D., McCredie, M., Giles, G., Chenevix-Trench, G. (2002). The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics and Genomics, 12(5), 355-366.
  • Goodwin, B., Hodgson, E., D'Costa, D., Robertson, G., Liddle, C. (2002). Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Molecular Pharmacology, 62, 359-365.

2001

  • Amr, D., Liddle, C. (2001). A novel polymorphism affects transcription of the CYP3A4 gene. Journal of Gastroenterology and Hepatology, 16.
  • Stedman, C., Robertson, G., Liddle, C., Field, J. (2001). Hepatoprotective response to cholestasis: bile duct ligation activates transcription of a human activates transcription of a human CYP3A4/LACZ transgene in mice. Journal of Gastroenterology and Hepatology, 16.
  • Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum leptin is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Journal of Gastroenterology and Hepatology, 16.
  • Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.

To update your profile click here. For support on your academic profile contact .